SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
liv12605-sup-0001-FigS1A.tifimage/tif117KFig. S1. Antiviral responses during 24 months of therapy in cirrhotic patients without hepatocellular carcinoma.
liv12605-sup-0002-FigS1B.tifimage/tif85K 
liv12605-sup-0003-FigS1C.tifimage/tif126K 
liv12605-sup-0004-FigS1D.tifimage/tif327K 
liv12605-sup-0002-FigS2.pptxapplication/mspowerpoint73KFig. S2. Levels of total bilirubin, albumin, INR, CTP score and MELD score at baseline, 12 months and 24 months after TBV and ETV therapy in cirrhotic patients without hepatocellular carcinoma (Data are presented as mean ± standard deviation).
liv12605-sup-0006-TableS1-S2.docxWord document15K

Table S1. Serologic and biochemical response during 24 months of treatment with telbivudine and entecavir in cirrhosis patients without hepatocellular carcinoma.

Table S2. Comparison of changes in hepatic function after 24 months of treatment with telbivudine and entecavir in cirrhosis patents without hepatocellular carcinoma.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.